Content
06/29/2022
San Jose, CA USA
Visby Medical
completed $135 million Series E Round funding. Investors include
Lightrock (lead), Cedars Sinai Health Ventures, +ND Capital, Artiman Ventures, Pitango Venture Capital, J Ventures.
About
Founded in 2012, Visby Medical, Inc. is revolutionizing infectious disease diagnosis by empowering both physicians and patients to accurately test for infections anywhere, anytime, with laboratory accuracy. The company's proprietary technology platform delivers true PCR results in under 30 minutes through the world's first instrument-free, single-use PCR tests that fit in the palm of your hand. Currently, Visby Medical offers FDA-cleared tests for sexually transmitted infections (STIs), available both in point-of-care settings and now directly to consumers at home, and respiratory infections (COVID-19, flu A and flu B), available for point-of-care settings. Visby Medical is actively expanding its platform with a wide range of future tests for the at-home and point-of-care markets.
Startup
Sector:
Healthcare
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
